Leaps by Bayer backed the gene-editing technology provider’s latest round, almost three years after it merged with existing Pairwise investor Monsanto Growth Ventures.
Pairwise Plants, a US-based developer of crop genome modification technology, completed a $90m series B round yesterday that included pharmaceutical and chemicals group Bayer’s corporate venturing arm, Leaps by Bayer.
Pontifax Global Food and Agriculture Technology Fund, the growth capital firm also known as Pontifax AgTech, co-led the round with healthcare investment firm Deerfield Management Company, and it included Singaporean state-owned investment vehicle Temasek.
Founded in 2017, Pairwise has developed an agricultural gene-editing platform that enhances the quality of produce…